ATE530165T1 - Alpha1-antitrypsin-zusammensetzungen und behandlungsverfahren unter verwendung dieser zusammensetzungen - Google Patents
Alpha1-antitrypsin-zusammensetzungen und behandlungsverfahren unter verwendung dieser zusammensetzungenInfo
- Publication number
- ATE530165T1 ATE530165T1 AT04811377T AT04811377T ATE530165T1 AT E530165 T1 ATE530165 T1 AT E530165T1 AT 04811377 T AT04811377 T AT 04811377T AT 04811377 T AT04811377 T AT 04811377T AT E530165 T1 ATE530165 T1 AT E530165T1
- Authority
- AT
- Austria
- Prior art keywords
- compositions
- treatment methods
- antitrypsin
- aat
- alpha1 antitrypsin
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 7
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 title abstract 2
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 title abstract 2
- 229940024142 alpha 1-antitrypsin Drugs 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 abstract 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 abstract 1
- 208000019693 Lung disease Diseases 0.000 abstract 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 abstract 1
- 239000000443 aerosol Substances 0.000 abstract 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 abstract 1
- 239000003963 antioxidant agent Substances 0.000 abstract 1
- 230000003078 antioxidant effect Effects 0.000 abstract 1
- 150000001720 carbohydrates Chemical class 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 239000012669 liquid formulation Substances 0.000 abstract 1
- 238000002663 nebulization Methods 0.000 abstract 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 abstract 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 abstract 1
- 229920000053 polysorbate 80 Polymers 0.000 abstract 1
- 229940068968 polysorbate 80 Drugs 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 230000000087 stabilizing effect Effects 0.000 abstract 1
- 239000004094 surface-active agent Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- -1 trehalose Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8121—Serpins
- C07K14/8125—Alpha-1-antitrypsin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Otolaryngology (AREA)
- Dispersion Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52054903P | 2003-11-14 | 2003-11-14 | |
| PCT/US2004/038650 WO2005048985A2 (en) | 2003-11-14 | 2004-11-11 | Alpha 1-antitrypsin compositions and treatment methods using such compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE530165T1 true ATE530165T1 (de) | 2011-11-15 |
Family
ID=34619481
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04811377T ATE530165T1 (de) | 2003-11-14 | 2004-11-11 | Alpha1-antitrypsin-zusammensetzungen und behandlungsverfahren unter verwendung dieser zusammensetzungen |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20080312136A1 (de) |
| EP (1) | EP1684719B1 (de) |
| JP (1) | JP2007511539A (de) |
| AT (1) | ATE530165T1 (de) |
| AU (1) | AU2004290587B2 (de) |
| CA (1) | CA2545855A1 (de) |
| DK (1) | DK1684719T3 (de) |
| ES (1) | ES2375706T3 (de) |
| PL (1) | PL1684719T3 (de) |
| PT (1) | PT1684719E (de) |
| SI (1) | SI1684719T1 (de) |
| WO (1) | WO2005048985A2 (de) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007528409A (ja) * | 2004-03-09 | 2007-10-11 | アリバ ファーマシューティカルズ， インコーポレイテッド | プロテアーゼインヒビターの低用量吸入による慢性閉塞性肺疾患の処置 |
| WO2009074634A2 (en) * | 2007-12-13 | 2009-06-18 | Glaxo Group Limited | Compositions for pulmonary delivery |
| CA2641872A1 (en) * | 2006-02-09 | 2007-08-16 | Kamada Ltd. | Alpha-i antitrypsin for treating exacerbation episodes of pulmonary diseases |
| EP2496246B1 (de) * | 2009-11-03 | 2018-06-27 | Grifols Therapeutics LLC | Zusammensetzung, verfahren und kit für einen alpha-1-proteasehmmer |
| HUE037733T2 (hu) | 2009-11-24 | 2018-09-28 | Grifols Therapeutics Inc | Liofilizálási eljárások, készítmények, és készletek |
| CA2785585A1 (en) * | 2009-12-22 | 2011-06-30 | Celldex Therapeutics, Inc. | Vaccine compositions |
| EP2758065B1 (de) | 2011-12-30 | 2021-06-23 | Grifols, S.A. | Alpha1-proteinasehemmer zur verwendung bei der verzögerung des beginns oder fortschreitens von lungenexazerbationen |
| WO2014160768A1 (en) * | 2013-03-29 | 2014-10-02 | The Regents Of The University Of Colorado | Compositions and methods for preparing a subject for organ or non-organ implantation |
| WO2015191892A2 (en) * | 2014-06-11 | 2015-12-17 | Beth Israel Deaconess Medical Center, Inc. | α1-ANTITRYPSIN COMPOSITIONS AND METHODS OF TREATING AUTOIMMUNE DISEASES |
| US20210085764A1 (en) * | 2016-12-22 | 2021-03-25 | Kamada Ltd. | Dry powder formulations of alpha-1 antitrypsin |
| WO2018154568A1 (en) * | 2017-02-21 | 2018-08-30 | Kamada Ltd. | Methods and uses of alpha 1-antitrypsin for early intervention in pulmonary diseases |
| WO2018183705A1 (en) | 2017-03-29 | 2018-10-04 | Cornell University | Oxidation-resistant aat gene therapy |
| US20200282031A1 (en) * | 2017-10-31 | 2020-09-10 | Kamada Ltd. | Methods and compositions for reducing lung injury associated with lung transplantation |
| IL267923B2 (en) * | 2018-08-02 | 2023-06-01 | Grifols Worldwide Operations Ltd | The composition containing the most concentrated alpha-1 type protein inhibitor and a method for obtaining it |
| CN120285204A (zh) * | 2018-10-23 | 2025-07-11 | G·E·霍格 | 用于治疗肺的组合物和方法 |
| EP4077688A1 (de) * | 2019-12-20 | 2022-10-26 | Krystal Biotech, Inc. | Zusammensetzungen und verfahren zur genabgabe an die atemwege und/oder lunge |
| GB202102258D0 (en) * | 2021-02-17 | 2021-03-31 | Arecor Ltd | Novel composition |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4150071A (en) * | 1977-08-26 | 1979-04-17 | Respiratory Care, Inc. | Nebulizer |
| IT1105653B (it) * | 1978-06-20 | 1985-11-04 | Craighero Margherita | Apparecchio aerosolizzatore |
| US4253468A (en) * | 1978-08-14 | 1981-03-03 | Steven Lehmbeck | Nebulizer attachment |
| US4198969A (en) * | 1978-10-06 | 1980-04-22 | Baxter Travenol Laboratories, Inc. | Suction-operated nebulizer |
| US4453542A (en) * | 1980-12-08 | 1984-06-12 | Vortran Corporation | Vortex-generating medical products |
| US4775622A (en) * | 1982-03-08 | 1988-10-04 | Genentech, Inc. | Expression, processing and secretion of heterologous protein by yeast |
| US4599311A (en) * | 1982-08-13 | 1986-07-08 | Kawasaki Glenn H | Glycolytic promotersfor regulated protein expression: protease inhibitor |
| US5218091A (en) * | 1982-08-13 | 1993-06-08 | Zymogenetics, Inc. | Glycolytic promoters for regulated protein expression: protease inhibitor |
| US5010003A (en) * | 1983-04-25 | 1991-04-23 | Genentech, Inc. | Use of yeast homologous signals to secrete heterologous proteins |
| US4620670A (en) * | 1983-11-28 | 1986-11-04 | Vortran Corporation | Gas-powered nebulizer |
| US4711848A (en) | 1984-03-14 | 1987-12-08 | Zymogenetics, Inc. | Site specific mutagenesis in alpha-1-antitrypsin |
| US4940661A (en) * | 1984-05-17 | 1990-07-10 | Genentech, Inc. | Metallothionein transcription control sequences and use thereof |
| US4931373A (en) * | 1984-05-25 | 1990-06-05 | Zymogenetics, Inc. | Stable DNA constructs for expression of α-1 antitrypsin |
| US4732973A (en) * | 1984-06-14 | 1988-03-22 | Chiron Corporation | Active site modified protease α-1-antitrypsin inhibitors |
| US4752576A (en) * | 1984-06-14 | 1988-06-21 | Chiron Corporation | Expression of α-1 antitrypsin in yeast |
| US4837148A (en) * | 1984-10-30 | 1989-06-06 | Phillips Petroleum Company | Autonomous replication sequences for yeast strains of the genus pichia |
| US5013652A (en) * | 1986-10-14 | 1991-05-07 | Genex Corporation | Composite yeast vectors |
| US5166134A (en) * | 1986-12-24 | 1992-11-24 | John Lezdey | Treatment of allergic rhinitis |
| US5093316A (en) * | 1986-12-24 | 1992-03-03 | John Lezdey | Treatment of inflammation |
| US4839283A (en) * | 1986-12-30 | 1989-06-13 | Zymogenetics, Inc. | Method of expressing alpha-1-antitrypsin in yeast |
| JP2656944B2 (ja) * | 1987-04-30 | 1997-09-24 | クーパー ラボラトリーズ | タンパク質性治療剤のエアロゾール化 |
| US4929555A (en) * | 1987-10-19 | 1990-05-29 | Phillips Petroleum Company | Pichia transformation |
| US6068994A (en) * | 1989-08-07 | 2000-05-30 | Chiron Corporation | Ubiquitin expression system |
| FR2660509B1 (fr) * | 1990-03-29 | 1993-11-19 | Alcatel Cit | Etage differentiel de sortie d'equipement electronique. |
| US5012652A (en) * | 1990-09-21 | 1991-05-07 | Carrier Corporation | Crankcase heater control for hermetic refrigerant compressors |
| US5134119A (en) | 1990-10-16 | 1992-07-28 | Lezdey John | Treatment of inflammation using 358 substituted alpha-antitrypsin |
| US5268384A (en) * | 1990-11-21 | 1993-12-07 | Galardy Richard E | Inhibition of angiogenesis by synthetic matrix metalloprotease inhibitors |
| US5114953A (en) * | 1990-11-21 | 1992-05-19 | University Of Florida | Treatment for tissue ulceration |
| US5892112A (en) * | 1990-11-21 | 1999-04-06 | Glycomed Incorporated | Process for preparing synthetic matrix metalloprotease inhibitors |
| US5256657A (en) * | 1991-08-19 | 1993-10-26 | Sterling Winthrop, Inc. | Succinamide derivative matrix-metalloprotease inhibitors |
| TW282490B (de) * | 1992-12-15 | 1996-08-01 | Ciba Geigy Ag | |
| US5594106A (en) * | 1993-08-23 | 1997-01-14 | Immunex Corporation | Inhibitors of TNF-α secretion |
| ATE226249T1 (de) * | 1994-08-05 | 2002-11-15 | Chiron Corp | Herstellung des inhibitors fuer die komplexbildung des gewebefaktors |
| US5780014A (en) * | 1995-04-14 | 1998-07-14 | Inhale Therapeutic Systems | Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin |
| US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| US5780440A (en) * | 1996-06-17 | 1998-07-14 | Protease Sciences Inc. | Treatment of pulmonary disease with protease inhibitors |
| US6610683B2 (en) * | 1996-09-12 | 2003-08-26 | Idun Pharmaceuticals, Inc. | Treatment of infectious disease using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors |
| EP0852951A1 (de) * | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern |
| DK0911416T3 (da) * | 1997-10-01 | 2006-08-14 | Dsm Ip Assets Bv | Fremgangsmåde til fremstilling af protein |
| US20010006939A1 (en) * | 1997-10-03 | 2001-07-05 | Ralph W. Niven | Secretory leukocyte protease inhibitor dry powder pharmaceutical compositions |
| US5972986A (en) * | 1997-10-14 | 1999-10-26 | G.D. Searle & Co. | Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia |
| AU1905799A (en) * | 1997-12-22 | 1999-07-12 | Human Genome Sciences, Inc. | Keratinocyte growth factor-2 formulations |
| WO1999032150A1 (en) * | 1997-12-23 | 1999-07-01 | Warner-Lambert Company | Ace inhibitor-mmp inhibitor combinations |
| JP2000247903A (ja) * | 1999-03-01 | 2000-09-12 | Chugai Pharmaceut Co Ltd | 長期安定化製剤 |
| WO2000051623A2 (en) * | 1999-03-05 | 2000-09-08 | The Trustees Of University Technology Corporation | Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide-induced clinical conditions |
| HK1054232A1 (zh) * | 2000-01-31 | 2003-11-21 | 辉瑞产品公司 | 用作pde4同工酶抑制剂的嘧啶甲酰胺 |
| GB0008660D0 (en) * | 2000-04-07 | 2000-05-31 | Arakis Ltd | The treatment of respiratory diseases |
| US6991824B2 (en) * | 2000-05-02 | 2006-01-31 | Ventria Bioscience | Expression of human milk proteins in transgenic plants |
| US20020099013A1 (en) * | 2000-11-14 | 2002-07-25 | Thomas Piccariello | Active agent delivery systems and methods for protecting and administering active agents |
| US7247704B2 (en) * | 2000-12-18 | 2007-07-24 | Arriva Pharmaceuticals, Inc. | Multifunctional protease inhibitors and their use in treatment of disease |
| PA8539301A1 (es) * | 2001-02-14 | 2002-09-30 | Warner Lambert Co | Inhibidores de la metaloproteinasa de la matriz |
| US6544497B2 (en) * | 2001-02-15 | 2003-04-08 | Aeropharm Technology Incorporated | Modulated release particles for aerosol delivery |
| JP2003024076A (ja) * | 2001-07-12 | 2003-01-28 | Kirin Brewery Co Ltd | Ｔｐｏ変異体タンパク質 |
| FR2832569B1 (fr) * | 2001-11-22 | 2007-04-27 | Evolium Sas | Procede de transmission de communications dans un systeme de telecommunication de type cellulaire utilisant des bandes de frequences porteuses adjacentes |
| US20030211548A1 (en) * | 2002-01-29 | 2003-11-13 | Oncolmmunin, Inc. | Visualization and quantitiation of cellular cytotoxicity using cell-permeable fluorogenic protease substrates and caspase activity indicator markers |
| JP2007534633A (ja) * | 2003-11-10 | 2007-11-29 | アライバ−プロメティック インコーポレイティド | ヒト・アルファ１−抗トリプシン製剤 |
-
2004
- 2004-11-11 DK DK04811377.3T patent/DK1684719T3/da active
- 2004-11-11 CA CA002545855A patent/CA2545855A1/en not_active Abandoned
- 2004-11-11 EP EP04811377A patent/EP1684719B1/de not_active Expired - Lifetime
- 2004-11-11 US US10/579,088 patent/US20080312136A1/en not_active Abandoned
- 2004-11-11 ES ES04811377T patent/ES2375706T3/es not_active Expired - Lifetime
- 2004-11-11 JP JP2006540034A patent/JP2007511539A/ja active Pending
- 2004-11-11 AT AT04811377T patent/ATE530165T1/de active
- 2004-11-11 WO PCT/US2004/038650 patent/WO2005048985A2/en active Application Filing
- 2004-11-11 SI SI200431814T patent/SI1684719T1/sl unknown
- 2004-11-11 PT PT04811377T patent/PT1684719E/pt unknown
- 2004-11-11 AU AU2004290587A patent/AU2004290587B2/en not_active Ceased
- 2004-11-11 PL PL04811377T patent/PL1684719T3/pl unknown
-
2010
- 2010-02-26 US US12/714,432 patent/US20100286066A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| SI1684719T1 (sl) | 2012-07-31 |
| JP2007511539A (ja) | 2007-05-10 |
| US20100286066A1 (en) | 2010-11-11 |
| EP1684719B1 (de) | 2011-10-26 |
| PL1684719T3 (pl) | 2012-11-30 |
| AU2004290587A1 (en) | 2005-06-02 |
| ES2375706T3 (es) | 2012-03-05 |
| CA2545855A1 (en) | 2005-06-02 |
| WO2005048985A2 (en) | 2005-06-02 |
| AU2004290587B2 (en) | 2010-08-12 |
| PT1684719E (pt) | 2012-02-03 |
| EP1684719A2 (de) | 2006-08-02 |
| DK1684719T3 (da) | 2012-01-30 |
| US20080312136A1 (en) | 2008-12-18 |
| WO2005048985A3 (en) | 2006-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE530165T1 (de) | Alpha1-antitrypsin-zusammensetzungen und behandlungsverfahren unter verwendung dieser zusammensetzungen | |
| NO20042596L (no) | Inbibitorer av 11-beta-hydroksy steroid dehydrogenase type 1 | |
| EP4442241A3 (de) | Retinolersatz zur hautbehandlung | |
| NO20060978L (no) | Farmasoytiske blandingr for behandling av prematur ejakulasjon ved pulmonal inhalering | |
| GEP20115205B (en) | Controlled release sterile injectable aripiprazole formulation and method | |
| NO20064347L (no) | Substituerte 1,2,3,4-tetrahydroisokinolinderivater | |
| MXPA04004842A (es) | Inhibidores de 11-(-hidroxiesteroide deshidrogenasa de tipo 1. | |
| DE60325379D1 (de) | Zusammensetzung enthaltend 6-Ä3-(1-adamantyl)-4-methoxyphenylÜ-2-naphthanoesäure zur Behandlung dermatologischer Erkrankungen | |
| NO20073059L (no) | 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists | |
| NO20055892L (no) | Karboksylsyrederivater | |
| DK1259240T3 (da) | Midler, såsom nikotinamid eller CADPR, til behandling af hudsygdomme | |
| MY143795A (en) | Tetrahydropyridoindole derivatives | |
| MY204380A (en) | Nonracemic mixtures and uses thereof | |
| RS11104A (en) | Combined preparations,containing 1,4- benzothiepine-1,1- dioxide derivatives and other active substances, and the use thereof | |
| BG106155A (en) | Novel derivatives and analogues of galanthamin | |
| AU2108500A (en) | Galenic formulation containing biotin | |
| RS44204A (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | |
| MXPA06000243A (es) | Formulacion farmaceutica liofilizada estable de tetrodotoxina. | |
| EP1284265A4 (de) | Benzothiophenderivate und deren medizinische verwendungen | |
| NO20073575L (no) | Farmasoytiske sammensetninger for behandling av cellulitt | |
| PA8525801A1 (es) | Compuestos de pirazol, composiciones farmacéuticas, y métodos para modular y/o inhibir la actividad de erab/hadh2 | |
| WO2003050067A3 (fr) | Analogues de la vitamine d | |
| WO2006032115A3 (en) | Composition against cardiovascular diseases | |
| AR026631A1 (es) | ''3-4-dihidroquinazolinas 5,6-disustituidas'' | |
| DE50310932D1 (de) | Sporopollenin enthaltende lösliche zusammensetzung und verwendung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1684719 Country of ref document: EP |